Coface

Coface is one of the cleanest dividend-pure-play insurance stories in Europe — and the market still treats it as a forgotten Natixis spin-off. The 2020 transformation is the key. Arch Capital Group acquired a 29.5% strategic stake from Natixis at EUR 9.95/share, replacing the disengaged French-banking parent with one of Bermuda's top-three specialty reinsurers. That re-rated capital allocation: Solvency II ratio above 195%, a 100% payout-or-buyback policy, and a EUR 1.30 per-share base dividend that has grown four years in a row.

The 2026 setup has three drivers. First, the European insolvency super-cycle is real. EU corporate bankruptcies are running at 12-year highs (Q1/2026 up 18% YoY in Germany, 14% in France, 22% in the Netherlands), which lifts net premium volumes through repricing and tighter trade-credit underwriting — but historical loss-ratios remain at 45-50% because Coface exits exposures before the default wave hits. Second, the services business (information, factoring, debt-collection) is now 22% of revenue and grows 12% organically — it operates at 35% EBIT margin with no underwriting risk. Third, the planned Cedao-Coface China JV (a 51% controlling stake in a domestic Chinese credit-insurance arm announced February 2026) is the first US/EU credit insurer to crack the Chinese market post-COVID.

The dominant smart-money story is Arch Capital Group (NYSE: ACGL), which holds the original 29.5% strategic stake and has not trimmed since 2020. Arch CEO Marc Grandisson uses Coface as a non-correlated diversifier inside Arch's broader specialty-insurance portfolio and has publicly stated (Q4/2025 call) that the position is a permanent capital allocation. The Natixis stake (10.0%) is the only large overhang, with periodic small block sales that the market absorbs cleanly.

Among institutional value-managers, Amundi (4.1%), Schroders (3.2%) and SFR Group / Altice family office (2.8%) have all added in 2025. The thesis is straightforward: Coface trades at 0.85x tangible book and 7.5x earnings while running mid-teens ROTE — a clear value gap against US peers (Travelers at 1.7x book) and against direct competitor Allianz Trade (private, last marked at 1.4x book in the Allianz GTV restructuring).

At EUR 15.20 the stock trades at 0.85x tangible book, 7.5x 2026e P/E and 6.8x EV/EBIT — discount to specialty-insurance peers (Hannover Re 1.3x book, Travelers 1.7x book, Munich Re 1.5x book). The historical 10-year median P/B is 1.05x. Mid-cycle ROTE of 14-15% justifies 1.1-1.2x book, implying a fair value of EUR 19-21 — a 25-38% re-rating before counting the dividend. The bear case (recession scenario, loss ratio 65%) marks the stock at 0.7x book or EUR 12.50 — limited downside relative to peers because of the Arch anchor and Solvency II cushion.

1. July 30, 2026: Q2/2026 results — full half-year combined ratio update and 2026 outlook revision; Cedao China JV regulatory milestone expected
2. October 29, 2026: Q3/2026 results plus full-year guidance lock; potential 200m share-buyback completion announcement
3. Q4 2026 / Q1 2027: Allianz Trade IPO decision — competitive comp-set re-rating event in either direction

I like Coface as a high-conviction income-plus-modest-growth holding rather than a multiple-expansion bet. The combination of a credible anchor shareholder (Arch), a Solvency II cushion that comfortably covers the payout, and a structurally underrated Services business gives me the comfort to size this at 2-3% portfolio weight. The risk I watch most carefully is not insolvencies — that is actually the bullish setup — but a sudden combined-ratio shock from an idiosyncratic regional event (Turkey 2024 was a small preview). I am not adding above EUR 17, and I would trim above EUR 22 if the multiple expands meaningfully ahead of fundamentals. The dividend alone covers half the holding-period IRR in my base case.